Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis

Peginterferon beta‐1a reduced annualized relapse rate as compared with placebo and was approved to treat multiple sclerosis patients. A population pharmacokinetic and an exposure‐efficacy model were developed to establish the quantitative relationship between pharmacokinetics and annualized relapse...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Pharmacol
Main Authors: Hu, Xiao, Hang, Yaming, Cui, Yue, Zhang, Jie, Liu, Shifang, Seddighzadeh, Ali, Deykin, Aaron, Nestorov, Ivan
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Pharmacometrics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5516189/
https://ncbi.nlm.nih.gov/pubmed/28394418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.883
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados